Avila, Jorge http://orcid.org/0000-0001-8973-5166
Leone, Julieta
Vallejo, Carlos T.
Lin, Nancy U.
Leone, José P.
Funding for this research was provided by:
Susan G. Komen (CCR19609014)
Article History
Received: 28 November 2023
Accepted: 8 February 2024
First Online: 7 March 2024
Declarations
:
: NUL received research funding from Genentech Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca and UpToDate; and consulting honoraria from Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, and Stemline/Menarini. JPL received research funding from Kazia Therapeutics and from Seagen; and consulting honoraria from Minerva Biotechnologies. All other authors have no conflicts.
: NUL received research funding from Genentech Pfizer, Merck, Seattle Genetics, Zion Pharmaceuticals, Olema Pharmaceuticals, AstraZeneca and UpToDate; and consulting honoraria from Puma, Seattle Genetics, Daichii-Sankyo, AstraZeneca, Denali Therapeutics, Prelude Therapeutics, Olema Pharmaceuticals, Aleta BioPharma, Affinia Therapeutics, Voyager Therapeutics, Janssen, Blueprint Medicines, and Stemline/Menarini. JPL received research funding from Kazia Therapeutics and from Seagen; and consulting honoraria from Minerva Biotechnologies. All other authors have no conflicts.
: This study was presented in poster format and in a poster discussion session at the 2022 San Antonio Breast Cancer Symposium, which took place from December 6–10 in San Antonio, TX, USA.